Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Accuray Incorporated (NASDAQ:ARAY), a company specializing in surgical and medical instruments with a market capitalization of $250 million, announced the appointment of Leonel Peralta as its new ...

Accuray Incorporated (NASDAQ:ARAY), a company specializing in surgical and medical instruments with a market capitalization of $250 million, announced the appointment of Leonel Peralta as its new ...

highlighted the CyberKnife System as an effective and time efficient treatment option for brain stem metastases. Additionally, in October, we announced the publication of the Accuray sponsored ...

Accuray Incorporated ARAY reported second ... was driven by robust growth in product revenue and solid demand for its CyberKnife system. ARAY’s shares moved north 6.8% and closed at $2.49 ...

Accuray Incorporated (NASDAQ ... always looking to improve patient care in the markets where we compete. The CyberKnife system which remains the only truly robotic radiotherapy system dedicated ...

For example, in December, the international Journal of Cancer, highlighted the CyberKnife System as an effective and time efficient treatment option for brain stem metastases. Additionally, in October ...